楊石

[摘要] 目的 觀察柳氮磺胺吡啶聯(lián)合雙歧三聯(lián)活菌膠囊治療輕中度潰瘍性結(jié)腸炎的臨床效果。 方法 將2012年6月～2014年6月在本院進行治療的、已確診的、符合納入標準的106例輕中度潰瘍性結(jié)腸炎患者隨機分為觀察組和對照組，每組53例。觀察組采用柳氮磺吡啶，1.0 g/次，4次/d，口服；聯(lián)合雙歧桿菌三聯(lián)活菌膠囊，0.63 g/次，3次/d，口服；兩種藥物服用時間間隔2 h。對照組單用柳氮磺吡啶，1.0 g/次，4次/d，口服。每周隨訪，治療12周后進行效果評估。 結(jié)果 觀察組排便次數(shù)、便血、內(nèi)鏡檢查及醫(yī)師總體評分均低于對照組，差異有統(tǒng)計學意義（P<0.01）；用改良Mayo評分比較，觀察組療效明顯優(yōu)于對照組，差異有統(tǒng)計學意義（P<0.01）。 結(jié)論 柳氮磺胺吡啶聯(lián)合雙歧三聯(lián)活菌膠囊治療潰瘍性結(jié)腸炎，可有效提高治療效果，改善患者的臨床癥狀，減少復發(fā)，值得推廣應用。

[關鍵詞] 潰瘍性結(jié)腸炎；柳氮磺胺吡啶；雙歧三聯(lián)活菌膠囊；改良Mayo評分

[中圖分類號] R574.62 [文獻標識碼] A [文章編號] 1674-4721（2015）02（b）-0114-03

Efficacy observation of Salazosulfapyridine combined with bifid triple viable capsules in treatment of mild moderate ulcerative colitis

YANG Shi LIU Yun-yang YU Ying YAO Jia-ru

Qishi Hospital of Dongguan City in Guangdong Province，Dongguan 523500，China

[Abstract] Objective To observe the clinical effects of Salazosulfapyridine combined with bifid triple viable capsules in treatment of mild moderate ulcerative colitis. Methods 106 patients with mild moderate ulcerative colitis treated in our hospital from June 2012 to June 2014，confirmed and met the inclusion criteria were selected，and were randomly divided into observation group and control group，53 cases in each group.In observation group，Salazosulfapyridine （1.0 g per time，4 times a day，oral） combined with bifid triple viable capsules （0.63 g per time，3 times a day，oral） were applied，and the interval time between two medications was 2 hours；while in control group，only Salazosulfapyridine （1.0 g per time，4 times a day，oral） was applied.Weekly follow-up was elaborated during the clinical process.After 12 weeks the treatment，the efficacy was compared. Results The defecation frequency，hemafecia condition，endoscopic examination and overall physician ratings in observation group was lower than that in control group，the differnece was significant （P<0.01）.According to modified Mayo score，the treatment effect of observation group was superior than that of control group，the differnece was significant （P<0.01）. Conclusion Salazosulfapyridine combined with bifid triple viable capsules in treatment of mild moderate ulcerative colitis can improve the clinical effect，mitigate clinical symptoms of patients，reduce the probability of recurrence，and is worthy of further promotion and application.

[Key words] Ulcerative colitis；Salazosulfapyridine；Bifid triple viable capsules；Modified Mayo score

潰瘍性結(jié)腸炎是一種病因尚不十分清楚的結(jié)腸和直腸慢性非特異性炎癥性疾病，病變局限于大腸黏膜及黏膜下層，多位于乙狀結(jié)腸和直腸，也可延伸至降結(jié)腸，甚至整個結(jié)腸，臨床表現(xiàn)主要包括腹痛、腹瀉和黏液膿血便，還可合并胃腸道外表現(xiàn)，如皮膚損害、關節(jié)炎等，其病程漫長，常反復發(fā)作。根據(jù)《炎癥性腸病診斷與治療的共識意見》（2012·廣州）治療輕中度潰瘍性結(jié)腸炎仍首選氨基水楊酸制劑，包括傳統(tǒng)的柳氮磺胺吡啶和其他各種不同類型的5-氨基水楊酸制劑[1]，本文采用柳氮磺胺吡啶聯(lián)合雙歧三聯(lián)合活菌膠囊治療輕中度潰瘍性結(jié)腸炎，觀察其臨床效果。